NiSOD-like Compound Suppressing Protein Aggregation in Neurodegeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders such as spinocerebellar ataxia, Alzheimer's disease, and Parkinson's disease are ineffective in suppressing abnormal protein aggregation and reducing oxidative stress, leading to progressive neuronal loss and dysfunction.
Innovation Solution
A NiSOD-like compound with specific structural formulas, such as five-coordinate and six-coordinate derivatives, is used to suppress abnormal protein aggregation, recover cell viability, increase mature neuron number, and protect dopaminergic cells by reducing oxidative stress or reactive oxygen species in brain tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurodegenerative disorders are used, then conventional therapy is provided, but they are ineffective in suppressing abnormal protein aggregation and reducing oxidative stress
Solution Approach 1:
The patent changes the chemical parameter by introducing nickel-containing superoxide dismutase (NiSOD) compounds with specific coordination structures (five-coordinate or six-coordinate nickel centers with nitrogen-donor ligands). This parameter change enables the compound to catalyze dismutation of superoxide radicals, directly addressing the oxidative stress problem that conventional treatments fail to address.
Solution Approach 2:
The NiSOD compound acts as an intermediary substance that mediates between the harmful superoxide radicals and the cellular environment. The nickel center serves as a catalytic intermediary that facilitates the conversion of toxic superoxide radicals into less harmful molecules (oxygen and hydrogen peroxide), thereby protecting neurons from oxidative damage without requiring direct intervention in the underlying protein aggregation pathology.
2Object-affected harmful factors
If protein aggregation is not suppressed, then neurodegeneration progresses, but suppressing protein aggregation and reducing oxidative stress is needed to inhibit harmful downstream events
Solution Approach 1:
The patent converts the harmful effect of superoxide radicals into a beneficial outcome by using NiSOD to catalyze their dismutation. The harmful superoxide radicals, which would otherwise cause oxidative damage and cell death, are transformed into beneficial or less harmful products (oxygen and hydrogen peroxide). This principle directly addresses the contradiction by turning the oxidative stress that threatens neuronal survival into a protective mechanism.
Solution Approach 2:
The NiSOD compound provides self-service functionality by directly neutralizing superoxide radicals in the cellular environment without requiring complex immune responses or external intervention systems. The nickel-containing catalyst continuously performs the dismutation reaction as long as superoxide radicals are present, creating a self-sustaining protective mechanism that maintains neuronal health autonomously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The NiSOD-like compound effectively reduces protein aggregation, enhances cell viability, increases neuron and neurite outgrowth, and protects dopaminergic cells, as demonstrated in various cell and animal models of neurodegenerative disorders, offering potential therapeutic benefits for these diseases.
Implementation Method 1
protecting dopaminergic cells by reducing oxidative stress or reactive oxygen species in brain tissues
Data Source
AI summary
The accumulation of abnormal proteins in neurodegenerative disorders is considered to induce oxidative stress and lead to cell death. Thus suppression of abnormal protein aggregation and reducing oxidative stress or reactive oxygen species (ROS) are expected to inhibit a wide range of harmful downstream events, providing an observation for identifying the potential prevention and treatment of neurodegenerative disorders comprising spinocerebellar ataxia (SCA), Alzheimer's disease (AD) or Parkinson's disease (PD). In the present invention, there are several cell and animal experiment models for SCA, AD and PD established, and NiSOD-like compounds were applied to these experiment models. The results have demonstrated how NiSOD-like compounds are likely to work in suppressing abnormal protein aggregation, recovering cell viability, increasing mature neuron number and neurite outgrowth length and protecting dopaminergic cells by reducing oxidative stress or reactive oxygen species in brain tissues.